Advertisement

Rational Approach to Pediatric Antifungal Therapy

  • William J. Steinbach
Chapter
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 697)

Abstract

To begin a rational approach to the treatment of pediatric invasive fungal infections, one has to first correctly diagnose the infections. While this is not the focus of this review, the critical nature of the correct diagnosis cannot be overemphasized. For instance, medically important fungi can be generally divided into yeasts and molds, and often that simplistic delineation is the only result the clinician will have for many days while the microbiology laboratory is fully identifying the pathogen. However, even this initial distinction can be crucial to beginning empiric antifungal therapy in the highest risk patients. While a yeast infection can largely include Candida, Cryptococcus, or Trichosporon species, a mold infection is more complicated as they can be further subdivided into septate and aseptate (without hyphal septa).

Keywords

Antifungal Therapy Invasive Aspergillosis Invasive Fungal Infection Invasive Candidiasis Liposomal Amphotericin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Pappas PG, Kauffman CA, Andes D, Benjamin DKJ, Calandra TF, Edwards JEJ et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the infectious diseases society of America. Clin Infect Dis. 2009;48:503–35.CrossRefPubMedGoogle Scholar
  2. 2.
    Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA et al. Treatment of aspergillosis: clinical practice guidelines of the infectious diseases society of America. Clin Infect Dis. 2008;46:327–60.CrossRefPubMedGoogle Scholar
  3. 3.
    Steinbach WJ, Stevens DA. Review of newer antifungal and immunomodulatory strategies for invasive aspergillosis. Clin Infect Dis. 2003;37(Suppl 3):S157–S87.CrossRefPubMedGoogle Scholar
  4. 4.
    Dismukes WE. Introduction to antifungal agents. Clin Infect Dis. 2000;30:653–7.CrossRefPubMedGoogle Scholar
  5. 5.
    Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002;347(6):408–15.CrossRefPubMedGoogle Scholar
  6. 6.
    Patterson TF, Boucher HW, Herbrecht R, Denning DW, Lortholary O, Ribaud P et al. Strategy of following voriconazole versus amphotericin B therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: impact of other therapies on outcome. Clin Infect Dis. 2005;41(10):1448–52.CrossRefPubMedGoogle Scholar
  7. 7.
    Walsh TJ, Lutsar I, Driscoll T, Dupont B, Roden M, Ghahramani P et al. Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. Pediatr Infect Dis J. 2002;21(3):240–8.CrossRefPubMedGoogle Scholar
  8. 8.
    Cesaro S, Strugo L, Alaggio R, Cecchetto G, Rigobello L, Pillon M et al. Voriconazole for invasive aspergillosis in oncohematological patients: a single-center pediatric experience. Support Care Cancer. 2003;11(11):722–7.CrossRefPubMedGoogle Scholar
  9. 9.
    Walsh TJ, Viviani MA, Arathoon E, Chiou C, Ghannoum M, Groll AH et al. New targets and delivery systems for antifungal therapy. Med Mycol. 2000;38 Suppl 1:335–47.PubMedGoogle Scholar
  10. 10.
    Maertens J, Raad I, Petrikkos G, Boogaerts M, Selleslag D, Petersen FB et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis. 2004;39(11):1563–71.CrossRefPubMedGoogle Scholar
  11. 11.
    Trenschel R, Ditschkowski M, Elmaagacli AH, Koldehoff M, Ottinger H, Steckel N et al. Caspofungin as second-line therapy for fever of unknown origin or invasive fungal infection following allogeneic stem cell transplantation. Bone Marrow Transplant. 2005;35(6):583–6.CrossRefPubMedGoogle Scholar
  12. 12.
    Candoni A, Mestroni R, Damiani D, Tiribelli M, Michelutti A, Silvestri F et al. Caspofungin as first line therapy of pulmonary invasive fungal infections in 32 immunocompromised patients with hematologic malignancies. Eur J Haematol. 2005;75(3):227–33.CrossRefPubMedGoogle Scholar
  13. 13.
    Tawara S, Ikeda F, Maki K, Morishita Y, Otomo K, Teratani N et al. In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi. Antimicrob Agents Chemother. 2000;44:57–62.CrossRefPubMedGoogle Scholar
  14. 14.
    Denning DW, Marr KA, Lau WM, Facklam DP, Ratanatharathorn V, Becker C et al. Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J Infect. 2006 Nov;53(5):337–49.Google Scholar
  15. 15.
    Serrano Mdel C, Valverde-Conde A, Chavez MM, Bernal S, Claro RM, Peman J et al. In vitro activity of voriconazole, itraconazole, caspofungin, anidulafungin (VER002, LY303366) and amphotericin B against aspergillus spp. Diagn Microbiol Infect Dis. 2003;45(2):131–5.CrossRefPubMedGoogle Scholar
  16. 16.
    Bowman JC, Hicks S, Kurtz MB, Rosen H, Schmatz DM, Liberator PA et al. The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitro. Antimicrob Agents Chemother. 2002;46:3001–12.CrossRefPubMedGoogle Scholar
  17. 17.
    Ezzet F, Wexler D, Courtney R, Krishna G, Lim J, Laughlin M. Oral bioavailability of posaconazole in fasted healthy subjects: comparison between three regimens and basis for clinical dosage recommendations. Clin Pharmacokinet. 2005;44(2):211–20.CrossRefPubMedGoogle Scholar
  18. 18.
    Ullmann AJ, Cornely OA, Burchardt A, Hachem R, Kontoyiannis DP, Topelt K et al. Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrob Agents Chemother. 2006;50(2):658–66.CrossRefPubMedGoogle Scholar
  19. 19.
    Krishna G, Sansone-Parsons A, Martinho M, Kantesaria B, Pedicone L. Posaconazole plasma concentrations in juvenile patients with invasive fungal infection. Antimicrob Agents Chemother. 2007;51(3):812–18.CrossRefPubMedGoogle Scholar
  20. 20.
    Walsh TJ, Karlsson MO, Driscoll T, Arguedas AG, Adamson P, Saez-Llorens X et al. Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration. Antimicrob Agents Chemother. 2004;48(6):2166–72.CrossRefPubMedGoogle Scholar
  21. 21.
    Purkins L, Wood N, Ghahramani P, Greenhalgh K, Allen MJ, Kleinermans D. Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens. Antimicrob Agents Chemother. 2002;46(8):2546–53.CrossRefPubMedGoogle Scholar
  22. 22.
    Lazarus HM, Blumer JL, Yanovich S, Schlamm H, Romero A. Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection: a dose escalation study. J Clin Pharmacol. 2002;42(4):395–402.CrossRefPubMedGoogle Scholar
  23. 23.
    Karlsson MO, Lutsar I, Milligan PA. Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies. Antimicrob Agents Chemother. 2009;53:935–44.CrossRefPubMedGoogle Scholar
  24. 24.
    Walsh TJ, Driscoll TA, Arietta AC, Klein N, Bradley J, Hafri HS et al. Pharmacokinetics, safety, and tolerability of voriconazole in hospitalized children. In: ICAAC, San Francisco, CA, 2006.Google Scholar
  25. 25.
    Dodds Ashley ES, Zaas AK, Fang AF, Damle B, Perfect JR. Comparative pharmacokinetics of voriconazole administered orally as either crushed or whole tablets. Antimicrob Agents Chemother. 2007;51(3):877–80.CrossRefPubMedGoogle Scholar
  26. 26.
    Goldstein JA, de Morais SM. Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics. 1994;4(6):285–99.CrossRefPubMedGoogle Scholar
  27. 27.
    Smith J, Safdar N, Knasinski V, Simmons W, Bhavnani SM, Ambrose PG et al. Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother. 2006;50:1570–2.CrossRefPubMedGoogle Scholar
  28. 28.
    Lutsar I, Hodges MR, Tomaszewski K, Troke PF, Wood ND. Safety of voriconazole and dose individualization. Clin Infect Dis. 2003;36:1087–8.CrossRefPubMedGoogle Scholar
  29. 29.
    Polak A. The past, present, and future of antimycotic combination therapy. Mycoses. 1999;42:355–70.CrossRefPubMedGoogle Scholar
  30. 30.
    Lewis RE, Klepser ME, Pfaller MA. Combination systemic antifungal therapy for cryptococcosis, candidiasis, and aspergillosis. J Infect Dis Pharmacother. 1999;3:61–83.CrossRefGoogle Scholar
  31. 31.
    Popp AI, White MH, Quadri T, Walshe L, Armstrong D. AmphotericinB with and without itraconazole for invasive aspergillosis: a three-year retrospective study. Int J Infect Dis. 1999;3:157–60.CrossRefPubMedGoogle Scholar
  32. 32.
    Denning DW, Stevens DA. Antifungal and surgical treatment of invasive aspergillosis: review of 2,121 published cases. Rev Infect Dis. 1990;12:1147–200.PubMedGoogle Scholar
  33. 33.
    Verweij PE, Donnelly JP, Kullberg BJ, Meis JFGM, De Pauw BE. Amphotericin B versus amphotericin B plus 5-flucytosine: poor results in the treatment of proven systemic mycoses in neutropenic patients. Infection. 1994;22:81–5.CrossRefPubMedGoogle Scholar
  34. 34.
    Stevens DA, Kan VL, Judson MA, Morrison VA, Dummer S, Denning DW et al. Practice guidelines for diseases caused by Aspergillus. Clin Infect Dis. 2000;30:696–709.CrossRefPubMedGoogle Scholar
  35. 35.
    Steinbach WJ, Stevens DA, Denning DW. Combination and sequential antifungal therapy for invasive aspergillosis: review of published in vitro and in vivo interactions and 6281 clinical cases from 1966–2001. Clin Infect Dis. 2003;37(suppl 3):S188–S224.CrossRefPubMedGoogle Scholar
  36. 36.
    Marr KA, Boeckh M, Carter RA, Kim HW, Corey L. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis. 2004;39:797–802.CrossRefPubMedGoogle Scholar
  37. 37.
    Viscoli C. Combination therapy for invasive aspergillosis. Clin Infect Dis. 2004;39:803–5.CrossRefPubMedGoogle Scholar
  38. 38.
    Benjamin DKJ, Poole C, Steinbach WJ, Rowen JL, Walsh TJ. Neonatal candidemia and end-organ damage: a critical appraisal of the literature using meta-analytic techniques. Pediatrics. 2003;112(3 Pt 1):634–40.CrossRefPubMedGoogle Scholar
  39. 39.
    Wade KC, Wu D, Kaufman DA, Ward RM, Benjamin DK Jr, Sullivan JE et al. Population pharmacokinetics of fluconazole in young infants. Antimicrob Agents Chemother. 2008;52(11):4043–9.CrossRefPubMedGoogle Scholar
  40. 40.
    Kaufman D, Boyle R, Hazen KC, Patrie JT, Robinson M, Donowitz LG. Fluconazole prophylaxis against fungal colonization and infection in preterm infants. N Engl J Med. 2001;345:1660–6.CrossRefPubMedGoogle Scholar
  41. 41.
    Walsh TJ, Adamson PC, Seibel NL, Flynn PM, Neely MN, Schwartz C et al. Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents. Antimicrob Agents Chemother. 2005;49:4536–45.CrossRefPubMedGoogle Scholar
  42. 42.
    Neely M, Jafri HS, Seibel N, Knapp K, Adamson PC, Bradshaw SK et al. Pharmacokinetics and safety of caspofungin in older infants and toddlers. Antimicrob Agents Chemother. 2009;53:1450–6.CrossRefPubMedGoogle Scholar
  43. 43.
    Seibel NL, Schwartz C, Arrieta A, Flynn P, Shad A, Albano E et al. Safety, tolerability, and pharmacokinetics of Micafungin (FK463) in febrile neutropenic pediatric patients. Antimicrob Agents Chemother. 2005;49(8):3317–24.CrossRefPubMedGoogle Scholar
  44. 44.
    Queiroz-Telles F, Berezin E, Leverger G, Freire A, van der Vyver A, Chotpitayasunondh T et al. Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: substudy of a randomized double-blind trial. Pediatr Infect Dis J. 2008;27(9):820–6.CrossRefPubMedGoogle Scholar
  45. 45.
    Smith PB, Walsh TJ, Hope W, Arrieta A, Takada A, Kovanda LL et al. Pharmacokinetics of an elevated dosage of micafungin in premature neonates. Pediatr Infect Dis J. 2009;28:412–15.CrossRefPubMedGoogle Scholar
  46. 46.
    Reboli AC, Rotstein C, Pappas PG, Chapman SW, Kett DH, Kumar D et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med. 2007;356(24):2472–82.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Department of Pediatrics, Division of Pediatric Infectious DiseasesDuke UniversityDurhamUSA
  2. 2.Department of Molecular Genetics and MicrobiologyDuke UniversityDurhamUSA
  3. 3.International Pediatric Fungal NetworkDuke University Medical CenterDurhamUSA

Personalised recommendations